Roivant (ROIV) insider filing: $3.85 options granted, $14.8–$15 sales
Rhea-AI Filing Summary
Roivant Sciences Ltd. (ROIV) insider filing shows Eric Venker, President & Immunovant CEO, reporting option awards and multiple share sales. The Form 4 discloses grants of stock options exercisable at $3.85 covering 1,562,374 options in total (1,000,000 on 09/19/2025; 462,374 and 100,000 on 09/22/2025) with an April 19, 2032 expiration and vesting tied to a 04/20/2022 commencement schedule. The filing also reports open-market sales totaling 1,711,000 common shares across 09/19–09/23/2025 at weighted-average prices disclosed in ranges (examples: $14.95, $14.99, $15.01, $14.83), some effected pursuant to a Rule 10b5-1 trading plan adopted June 25, 2024. Post-transactions, reported beneficial ownership figures for common stock and underlying options are shown on the form.
Positive
- 1,562,374 stock options granted at a $3.85 exercise price, increasing potential long-term alignment with shareholders
- Sales disclosure includes explicit notice that some transactions were effected under a Rule 10b5-1 trading plan, which provides pre-clearance context
- Filing includes vesting schedule and option expiration date (04/19/2032), improving transparency
Negative
- Reported open-market sales total 1,711,000 common shares across 09/19–09/23/2025, reducing the reporting person's direct share holdings
- Sales executed at weighted-average prices in the approximately $14.83–$15.01 range, representing material monetization during the reporting period
Insights
TL;DR: Insider received sizeable option awards while executing significant open-market sales; activity is material for monitoring but appears structured.
The filing records grants of 1,562,374 stock options at a $3.85 exercise price, expiring 04/19/2032, which increase potential long-term equity exposure if exercised. Concurrently, the reporting person sold 1,711,000 common shares between 09/19 and 09/23/2025 at reported weighted-average prices in the ~$14.8–$15.0 range, with some sales under a Rule 10b5-1 plan. For investors, this combination changes reported short-term free float and signals exercise/monetization activity while preserving long-term option-based upside.
TL;DR: Disclosure is compliant and includes 10b5-1 plan notice; timing and amounts are clearly reported.
The Form 4 includes explicit statements about the Rule 10b5-1 trading plan and weighted-average pricing disclosures, and it is signed by an attorney-in-fact. The grant vesting schedule is documented and tied to continuous service from a 04/20/2022 commencement date. From a governance perspective, the filing provides the required transparency about material insider transactions and award mechanics.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Shares | 611,000 | $14.83 | $9.06M |
| Exercise | Stock Option (Right to Buy) | 462,374 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 100,000 | $0.00 | -- |
| Exercise | Common Shares | 462,374 | $3.85 | $1.78M |
| Exercise | Common Shares | 100,000 | $3.85 | $385K |
| Sale | Common Shares | 316,182 | $14.99 | $4.74M |
| Sale | Common Shares | 100,000 | $15.01 | $1.50M |
| Exercise | Stock Option (Right to Buy) | 1,000,000 | $0.00 | -- |
| Exercise | Common Shares | 1,000,000 | $3.85 | $3.85M |
| Sale | Common Shares | 683,818 | $14.95 | $10.22M |
Footnotes (1)
- The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 25, 2024. Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).
